作者
Mark Trinder, Yanan Wang, Christian M Madsen, Tatjana Ponomarev, Lubos Bohunek, Brendan A Daisely, HyeJin Julia Kong, Lisanne L Blauw, Børge G Nordestgaard, Anne Tybjærg-Hansen, Mark M Wurfel, James A Russell, Keith R Walley, Patrick CN Rensen, John H Boyd, Liam R Brunham
发表日期
2021/3/2
期刊
Circulation
卷号
143
期号
9
页码范围
921-934
出版商
Lippincott Williams & Wilkins
简介
Background
The high-density lipoprotein hypothesis of atherosclerosis has been challenged by clinical trials of cholesteryl ester transfer protein (CETP) inhibitors, which failed to show significant reductions in cardiovascular events. Plasma levels of high-density lipoprotein cholesterol (HDL-C) decline drastically during sepsis, and this phenomenon is explained, in part, by the activity of CETP, a major determinant of plasma HDL-C levels. We tested the hypothesis that genetic or pharmacological inhibition of CETP would preserve high-density lipoprotein levels and decrease mortality in clinical cohorts and animal models of sepsis.
Methods
We examined the effect of a gain-of-function variant in CETP (rs1800777, p.Arg468Gln) and a genetic score for decreased CETP function on 28-day sepsis survival using Cox proportional hazard models adjusted for age and sex in the UK Biobank (n=5949), iSPAAR …
引用总数